NCT03479814 is a NA clinical trial of IMRT-SIB plus sequential IG-RT boost in Rectal Cancer, sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna.

Who is sponsoring NCT03479814?

NCT03479814 is sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna.

What drugs are being tested in NCT03479814?

Interventions in NCT03479814: IMRT-SIB plus sequential IG-RT boost.

What condition does NCT03479814 study?

NCT03479814 studies Rectal Cancer, Radiotherapy, Neoadjuvant Treatment.

Is NCT03479814 still recruiting?

NCT03479814 is currently status unknown. Last updated 27 March 2018.

Last reviewed 2018-03-27 · How we verify

NCT03479814

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Adaptive Individualized High-Dose Radiotherapy Analysis-REctum-1 (AIDA-RE-1)

Status unknown NA Last updated 27 March 2018

What this trial tests

NA trial testing IMRT-SIB plus sequential IG-RT boost in Rectal Cancer in 9 participants. Status unknown.

Timeline

1 August 2016

Primary endpoint
1 January 2019

1 January 2019

Quick facts

Lead sponsor	IRCCS Azienda Ospedaliero-Universitaria di Bologna
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	9
Start date	1 August 2016
Primary completion	1 January 2019
Estimated completion	1 January 2019
Sites	1 location across Italy

Drugs / interventions tested

IMRT-SIB plus sequential IG-RT boost

Conditions studied

Rectal Cancer — all drugs for Rectal Cancer →
Radiotherapy — all drugs for Radiotherapy →
Neoadjuvant Treatment — all drugs for Neoadjuvant Treatment →

Sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna — full company profile →

Who can join

18 and older, any sex, with Rectal Cancer or Radiotherapy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Aim of the study is to evaluate achievement of complete pathologic response (pCR) in high-risk rectal cancer treated with neoadjuvant concomitant chemotherapy plus adaptive-intensity modulated imaging-guided radiotherapy

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Adaptive Individualized high-dose preoperAtive (AIDA) chemoradiation in high-risk rectal cancer: a phase II trial.
Guido A, Cuicchi D, Castellucci P, Cellini F, et al · · 2023 · cited 7× · PMID 36127416 · DOI 10.1007/s00259-022-05944-0

Verify or expand the search:

Other recruiting trials for Rectal Cancer

Currently open trials in the same condition.

NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
NCT07537998 — Antegrade Intestinal Fluid Reinfusion for Prevention of Low Anterior Resection Syndrome After Low Anterior Resection: a · Phase 2, PHASE3 · recruiting
NCT07501845 — Registry Maastro Applicator · recruiting
NCT07369531 — The Impact of Two-Stage Turnbull-Cutait Pull-Through Coloanal Anastomosis on Stoma-free Survival in Low Rectal Anal-pres · NA · recruiting
NCT07505472 — Efficacy and Safety Comparison of Short-course Radiotherapy Followed by CapeOX Chemotherapy Plus Toripalimab With or Wit · Phase 2, PHASE3 · recruiting

Other IRCCS Azienda Ospedaliero-Universitaria di Bologna trials

Trials by the same sponsor.

NCT06718049 — Role of Interleukin 18 (IL-18) and Interleukin 18 Binding Protein (IL-18BP) in the Diagnostic Work-up of Systemic Juveni · not yet recruiting
NCT07490392 — Growth and Endocrinological Outcomes in Patients Who Underwent or Did Not Undergo Haematopoietic Stem Cell Transplantati · not yet recruiting
NCT07483853 — Reliability and Validation of the WB-MRI Radiological Score in CRMO · recruiting
NCT07479121 — These Studies Assess Surgeons' Physical and Ergonomic Workloads. Study 1 Compares Laparoscopic vs. Hugo RAS Robotic Appr · NA · not yet recruiting
NCT07471009 — Development of Patient Derived Xenografts (PDXs) and Analysis of Tyrosine Kinase Receptor Expression in Patients With Sq · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03479814 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by IRCCS Azienda Ospedaliero-Universitaria di Bologna
Last refreshed: 27 March 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03479814.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing